What is Physiomics Plc?
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland.
PYC · Verdict
Limited reward · elevated risk
PYC's standout is balance sheet; profitability and cash flow weigh on the picture.
Based on 88% data coverage
PYC · Verdict
Current ratio 4.38
-53% net margin · -120% ROE
-70% free-cash-flow margin
Rev -1.9% CAGR · earnings +17.9%
Model-based scoring. For information only — not financial advice.
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 1.52M.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.